Actavis launches Finasteride as patent expires in France

Actavis launches Finasteride as patent expires in France

Reykjavik, Iceland, 24 June 2009 -- Actavis Group, the international generic pharmaceuticals company launched Finasteride in France on day one, when the originator's patent expired on Monday 22 June. The distribution of the product has already commenced.

Finasteride Actavis was launched by the company under its brand name, and at the same time by various Medis clients. Medis, Actavis' Third Party sales division, handles the sales of intellectual property and pharmaceutical products to other pharmaceutical companies in most EU nations and elsewhere and has marketing authorisations in over 50 countries.   Finasteride, used for the treatment of prostate cancer, is the generic equivalent of Merck's Proscar®. Finasteride Actavis is available in tablets of 5mg in France.   Finasteride Actavis was developed by Actavis in Iceland and has already been launched by Actavis and its third party clients in many other European countries and in the United States.   Actavis has well over 300 product and market launches on the Group's various markets to date in 2009. A number of the products were first to market or launched on patent expiry, including Finasteride, Gemcitabine and Pantoprazole in Western Europe; Fluvastatin SR, Levofloxacin, Nebivolol and Sildenafil in Eastern Europe; and Atorvastatin, Donepesil, Fludarabine, Fluvastatin SR, Gemcitabine, Irinotecan, Isosorbide Mononitrate, Levofloxacin, Pantoprazole and Salbutamol in other markets.    

About Actavis Group
Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals.  The company has operations in 40 countries, with more than 10,000 employees. More information about Actavis can be found on the group website:    

Enquiries Actavis Group Hjordis Arnadottir Director - External Communications Tel: (+354) 535 2300 / 840 7476 E-mail: [email protected]   Any statements contained in this press release that refer to Actavis' estimated or anticipated future results or future activities are forward-looking statements which reflect the Company's current analysis of existing trends, information and plans. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially depending on factors such as the availability of resources, the timing and effect of regulatory actions, the success of new products, the strength of competition, the success of research and development issues, unexpected contract breaches or terminations, exposure to product liability and other lawsuits, the effect of currency fluctuations and other factors.

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.